Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs PQR 309 (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- Sponsors PIQUR Therapeutics
- 19 Apr 2017 Last checked against ClinicalTrials.gov record.
- 13 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 13 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.